The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
NAD(P)H Oxidase and Multidrug Resistance Protein Genetic Polymorphisms Are Associated With Doxorubicin-Induced Cardiotoxicity
Abstract
Background—A significant number of patients treated with anthracyclines develop cardiotoxicity (anthracycline-induced cardiotoxicity [ACT]), mainly presenting as arrhythmias (acute ACT) or congestive heart failure (chronic ACT). There are no data on pharmacogenomic predictors of ACT. Methods and Results—We genotyped participants of the German non-Hodgkin lymphoma study (NHL-B) who were followed up for the development of heart failure for a median of >3 years. Single-nucleotide polymorphisms (SNPs) were selected from 82 genes with conceivable relevance to ACT. Of 1697 patients, 55 developed acute and 54 developed chronic ACT (cumulative incidence of either form, 3.2%). We detected 5 significant associations with polymorphisms of the NAD(P)H oxidase and doxorubicin efflux transporters. Chronic ACT was associated with a variant of the NAD(P)H oxidase subunit NCF4 (rs1883112, −212A→G; symbols with right-pointing arrows, as edited?‘ odds ratio [OR], 2.5; 95% CI, 1.3 to 5.0). Acute ACT was associated with the His72Tyr polymorphism in the p22phox subunit (rs4673; OR, 2.0; 95% CI, 1.0 to 3.9) and with the variant 7508T→A (rs13058338; OR, 2.6; 95% CI, 1.3 to 5.1) of the RAC2 subunit of the same enzyme. In agreement with these results, mice deficient in NAD(P)H oxidase activity, unlike wild-type mice, were resistant to chronic doxorubicin treatment. In addition, acute ACT was associated with the Gly671Val variant of the doxorubicin efflux transporter multidrug resistance protein 1 (MRP1) (OR, 3.6; 95% CI, 1.6 to 8.4) and with the Val1188Glu-Cys1515Tyr (rs8187694-rs8187710) haplotype of the functionally similar MRP2 (OR, 2.3; 95% CI, 1.0 to 5.4). Polymorphisms in adrenergic receptors previously demonstrated to be predictive of heart failure were not associated with ACT. Conclusions—Genetic variants in doxorubicin transport and free radical metabolism may modulate the individual risk to develop ACT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Aldose reductase induction: a novel response to oxidative stress of smooth muscle cells
Spycher, S. E., Tabataba‐Vakili, S., O’Donnell, V. B., Palomba, L., & Azzi, A. (1997) · The FASEB Journal · doi:10.1096/fasebj.11.2.9039961 · Cited by 144
RetractedHaploview: analysis and visualization of LD and haplotype maps
Barrett, J. C., Fry, B., Maller, J., & Daly, M. J. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bth457 · Cited by 14,525
Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037
Risk Factors for Doxorubicin-lnduced Congestive Heart Failure
VON HOFF, D. D., LAYARD, M. W., BASA, P., DAVIS, H. L., VON HOFF, A. L., ROZENCWEIG, M., & MUGGIA, F. M. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-5-710 · Cited by 2,391
Late Cardiac Effects of Doxorubicin Therapy for Acute Lymphoblastic Leukemia in Childhood
Lipshultz, S. E., Colan, S. D., Gelber, R. D., Perez-Atayde, A. R., Sallan, S. E., & Sanders, S. P. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103213241205 · Cited by 1,404
Cardiac Toxicity 4 to 20 Years After Completing Anthracycline Therapy
Steinherz, L. J. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03470120074036 · Cited by 989
Pollock, J. D., Williams, D. A., Gifford, M. A. C., Li, L. L., Du, X., Fisherman, J., Orkin, S. H., Doerschuk, C. M., & Dinauer, M. C. (1995) · Nature Genetics · doi:10.1038/ng0295-202 · Cited by 921
Reduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous Infusion
LEGHA, S. S., BENJAMIN, R. S., MACKAY, B., EWER, M., WALLACE, S., VALDIVIESO, M., RASMUSSEN, S. L., BLUMENSCHEIN, G. R., & FREIREICH, E. J. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-96-2-133 · Cited by 763
Anthracycline-Induced Cardiotoxicity
Shan, K., Lincoff, A. M., & Young, J. B. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00008 · Cited by 749
Pfreundschuh, M. (2004) · Blood · doi:10.1182/blood-2003-06-2095 · Cited by 717
Self-citationCui, Y., König, J., Buchholz, U., Spring, H., Leier, I., & Keppler, D. (1999) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)23190-4 · Cited by 676
Increased myocardial NADPH oxidase activity in human heart failure
Heymes, C., Bendall, J. K., Ratajczak, P., Cave, A. C., Samuel, J.-L., Hasenfuss, G., & Shah, A. M. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00471-6 · Cited by 579
Self-citationSmall, K. M., Wagoner, L. E., Levin, A. M., Kardia, S. L. R., & Liggett, S. B. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020803 · Cited by 530
Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy
Schwartz, R. G., McKenzie, W. B., Alexander, J., Sager, P., D'Souza, A., Manatunga, A., Schwartz, P. E., Berger, H. J., Setaro, J., Surkin, L., et al. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90212-9 · Cited by 510
Tissue distribution of the multidrug resistance protein.
Flens, M. J., Zaman, G. J., van der Valk, P., Izquierdo, M. A., Schroeijers, A. B., Scheffer, G. L., van der Groep, P., de Haas, M., Meijer, C. J. L. M., & Scheper, R. J. (1996) · Europe PMC (PubMed Central) · Cited by 473
Wijnholds, J., Evers, R., van Leusden, M. R., Mol, C. A. A. M., Zaman, G. J. R., Mayer, U., Beijnen, J. H., Valk, M. V. D., Krimpenfort, P., & Borst, P. (1997) · Nature Medicine · doi:10.1038/nm1197-1275 · Cited by 432
Wijnholds, J., de Lange, E. C. M., Scheffer, G. L., van den Berg, D.-J., Mol, C. A. A. M., van der Valk, M., Schinkel, A. H., Scheper, R. J., Breimer, D. D., & Borst, P. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8267 · Cited by 360
Trend Tests for Case-Control Studies of Genetic Markers: Power, Sample Size and Robustness
Freidlin, B., Zheng, G., Li, Z., & Gastwirth, J. L. (2002) · Human Heredity · doi:10.1159/000064976 · Cited by 338
Henderson, I. C., Allegra, J. C., Woodcock, T. M., Wolff, S., Bryan, S., Cartwright, K. J., Dukart, G., & Henry, D. W. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.5.560 · Cited by 246
Polymorphism of the NADH/NADPH Oxidase p22 phox Gene in Patients With Coronary Artery Disease
Inoue, N., Kawashima, S., Kanazawa, K., Yamada, S., Akita, H., & Yokoyama, M. (1998) · Circulation · doi:10.1161/01.cir.97.2.135 · Cited by 238
Guzik, T. J., West, N. E. J., Black, E., McDonald, D., Ratnatunga, C., Pillai, R., & Channon, K. M. (2000) · Circulation · doi:10.1161/01.cir.102.15.1744 · Cited by 236
TORTI, F. M., BRISTOW, M. R., HOWES, A. E., ASTON, D., STOCKDALE, F. E., CARTER, S. K., KOHLER, M., BROWN, B. W., & BILLINGHAM, M. E. (1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-99-6-745 · Cited by 215
BORJESSON, M. (2000) · European Heart Journal · doi:10.1053/euhj.1999.1994 · Cited by 206
Chemotherapy-Induced Cardiotoxicity: Current Practice and Prospects of Prophylaxis
Gharib, M. I., & Burnett, A. K. (2002) · European Journal of Heart Failure · doi:10.1016/s1388-9842(01)00201-x · Cited by 200
Hortobagyi, G. N., Frye, D., Buzdar, A. U., Ewer, M. S., Fraschini, G., Hug, V., Ames, F., Montague, E., Carrasco, C. H., Mackay, B., et al. (1989) · Cancer · doi:10.1002/1097-0142(19890101)63:1<37::aid-cncr2820630106>3.0.co;2-z · Cited by 198
Subcellular Localization and Activity of Multidrug Resistance Proteins
Rajagopal, A., & Simon, S. M. (2003) · Molecular Biology of the Cell · doi:10.1091/mbc.e02-11-0704 · Cited by 190
Andersson, B., & Sylvén, C. (1996) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(96)00098-8 · Cited by 153
Kaye, D. M., Smirk, B., Williams, C., Jennings, G., Esler, M., & Holst, D. (2003) · Pharmacogenetics · doi:10.1097/00008571-200307000-00002 · Cited by 149
Kaiser, U., Uebelacker, I., Abel, U. R., Birkmann, J., Trümper, L. H. P., Schmalenberg, H., Karakas, T., Metzner, B., HOSSFELD, D. K., Bischoff, H. G., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.075 · Cited by 139
Self-citationTouyz, R. M., Mercure, C., He, Y., Javeshghani, D., Yao, G., Callera, G. E., Yogi, Á., Lochard, N., & Reudelhuber, T. L. (2005) · Hypertension · doi:10.1161/01.hyp.0000158845.49943.5e · Cited by 134
Wyche, K. E., Wang, S. S., Griendling, K. K., Dikalov, S., Austin, H. D., Rao, S., Fink, B., Harrison, D. G., & Zafari, A. M. (2004) · Hypertension · doi:10.1161/01.hyp.0000126579.50711.62 · Cited by 134
Cardiac Toxicity of Antineoplastic Anthracyclines
Zucchi, R., & Danesi, R. (2003) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1568011033353434 · Cited by 129
Cahilly, C., Ballantyne, C. M., Lim, D., Gotto, A. M., & Marian, A. J. (2000) · Circulation Research · doi:10.1161/01.res.86.4.391 · Cited by 129
Conrad, S., Kauffmann, H.-M., Ito, K., Leslie, E. M., Deeley, R. G., Schrenk, D., & Cole, S. P. C. (2002) · Pharmacogenetics · doi:10.1097/00008571-200206000-00008 · Cited by 110
Price, M. O., Atkinson, S. J., Knaus, U. G., & Dinauer, M. C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200061200 · Cited by 108
Gardemann, A., Mages, P., Katz, N. R., Tillmanns, H., & Haberbosch, W. (1999) · Atherosclerosis · doi:10.1016/s0021-9150(99)00083-0 · Cited by 108
Conrad, S., Kauffmann, H.-M., Ito, K., Deeley, R. G., Cole, S. P. C., & Schrenk, D. (2001) · Journal of Human Genetics · doi:10.1007/s100380170017 · Cited by 87
Human Heart Cytosolic Reductases and Anthracycline Cardiotoxicity
Mordente, A., Meucci, E., Martorana, G. E., Giardina, B., & Minotti, G. (2001) · IUBMB Life · doi:10.1080/15216540252774829 · Cited by 85
Cai, Duarte, N., Wilcken, & Wang (1999) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.1999.00531.x · Cited by 74
Small, K. M., Wagoner, L. E., Levin, S. M., et al. (2003) · ACC Current Journal Review · doi:10.1016/s1062-1458(03)00063-1 · Cited by 73
Phosphorylated p40PHOX as a Negative Regulator of NADPH Oxidase
Lopes, L. R., Dagher, M., Gutierrez, A., Young, B. M., Bouin, A., Fuchs, A., & BABIOR, B. M. (2004) · Biochemistry · doi:10.1021/bi035636s · Cited by 72
Schmidt, A. G., Kadambi, V. J., Ball, N. A., Sato, Y., Walsh, R. A., Kranias, E. G., & Hoit, B. D. (2000) · Journal of Molecular and Cellular Cardiology · doi:10.1006/jmcc.2000.1209 · Cited by 68
Self-citationShimo-Nakanishi, Y., Hasebe, T., Suzuki, A., Mochizuki, H., Nomiyama, T., Tanaka, Y., Nagaoka, I., Mizuno, Y., & Urabe, T. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.01.043 · Cited by 62
Mordente, A., Minotti, G., Martorana, G. E., Silvestrini, A., Giardina, B., & Meucci, E. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00442-8 · Cited by 61
Dell’Acqua, G., Polishchuck, R. S., Fallon, J. T., & Gordon, J. W. (1999) · Human Gene Therapy · doi:10.1089/10430349950017950 · Cited by 26
(2000) · doi:10.1002/1098-2272(200101)20:1<4::aid-gepi2>3.0.co;2-t
Cited by
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,076
Doxorubicin pathways: pharmacodynamics and adverse effects
Thorn, C. F., Oshiro, C., Marsh, S., Hernandez-Boussard, T., McLeod, H., Klein, T. E., & Altman, R. B. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32833ffb56 · Cited by 1,648
Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies
Octavia, Y., Tocchetti, C. G., Gabrielson, K. L., Janssens, S., Crijns, H. J., & Moens, A. L. (2012) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2012.03.006 · Cited by 1,414
Rawat, P. S., Jaiswal, A., Khurana, A., Bhatti, J. S., & Navik, U. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111708 · Cited by 909
Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment
Volkova, M., & Russell, R. (2012) · Current Cardiology Reviews · doi:10.2174/157340311799960645 · Cited by 872
Metadata
- Authors
- Wojnowski, L., Kulle, B., Schirmer, M., Schlüter, G., Schmidt, A., Rosenberger, A., Vonhof, S., Bickeböller, H., Toliat, M. R., Suk, E.-K., Tzvetkov, M., Kruger, A., Seifert, S., Kloess, M., Hahn, H., Loeffler, M., Nürnberg, P., Pfreundschuh, M., Trümper, L., Brockmöller, J., & Hasenfuss, G.
- Venue
- Circulation
- Published
- 2005-12-13
- Volume
- 112
- Issue
- 24
- Pages
- 3754-3762
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2116678763
- Cited by
- 489
- References
- 46
- FWCI
- 9.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.